Literature DB >> 25535172

Cushing syndrome after bilateral lensectomy.

Karin Sofia Scherrer1, Marcus Weitz, Johannes Eisenack, Béatrice Truffer, Daniel Konrad.   

Abstract

UNLABELLED: Iatrogenic Cushing syndrome induced by oral and parenteral corticosteroid administration is a well-known complication, and necessary precautions have to be taken. Cushing syndrome, however, following treatment with glucocorticoid-containing eye drops is a very rare complication. To the best of our knowledge, there have been only four reported cases in the literature. Herein, we present an infant boy who developed Cushing syndrome after receiving dexamethasone-containing eye drops after bilateral cataract extraction to prevent postoperative inflammatory complications. At the age of 5 months, after approx. 3 months of dexamethasone therapy, the patient presented with cushingoid facies, nephrocalcinosis and failure to grow. Iatrogenic Cushing syndrome was diagnosed and dexamethasone-containing eye drops were reduced and eventually stopped. Follow-up examinations revealed catch-up growth.
CONCLUSION: Ocularly administered corticosteroids may have substantial systemic side effects in infants.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25535172     DOI: 10.1007/s00431-014-2477-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.

Authors:  Therdpong Tempark; Voraluk Phatarakijnirund; Susheera Chatproedprai; Suttipong Watcharasindhu; Vichit Supornsilchai; Siriwan Wananukul
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions.

Authors:  C A Findlay; J F Macdonald; A M Wallace; N Geddes; M D Donaldson
Journal:  BMJ       Date:  1998-09-12

4.  Systemic hypertension following ocular administration of 10 per cent phenylephrine in the neonate.

Authors:  V Borromeo-McGrail; J M Bordiuk; H Keitel
Journal:  Pediatrics       Date:  1973-06       Impact factor: 7.124

5.  Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis.

Authors:  J R Kerrigan; J D Veldhuis; S A Leyo; A Iranmanesh; A D Rogol
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

6.  Iatrogenic Cushing syndrome caused by ocular glucocorticoids in a child.

Authors:  Maria Francesca Messina; Mariella Valenzise; Salvatore Aversa; Teresa Arrigo; Filippo De Luca
Journal:  BMJ Case Rep       Date:  2009-05-08

7.  Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis.

Authors:  U Ozerdem; L Levi; L Cheng; M K Song; C Scher; W R Freeman
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

8.  Fluorinated corticosteroid toxicity in infants.

Authors:  P E Romano; H S Traisman; O C Green
Journal:  Am J Ophthalmol       Date:  1977-08       Impact factor: 5.258

9.  Inappropriate use of potent topical glucocorticoids in infants.

Authors:  Alev Ozon; Semra Cetinkaya; Ayfer Alikasifoglu; E Nazli Gonc; Yaşar Sen; Nurgün Kandemir
Journal:  J Pediatr Endocrinol Metab       Date:  2007-02       Impact factor: 1.634

10.  Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled.

Authors:  Alan P Demayo; Marcus M Reidenberg
Journal:  Pediatrics       Date:  2004-05       Impact factor: 7.124

View more
  1 in total

Review 1.  Systemic side effects of eye drops: a pharmacokinetic perspective.

Authors:  Andre Farkouh; Peter Frigo; Martin Czejka
Journal:  Clin Ophthalmol       Date:  2016-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.